Sells cell-based cartilage treatments and burn-care products to hospitals and burn centers, serving orthopedic surgeons and burn-care teams.
10-K for FY2025, filed Feb 26, 2026Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly…View ↗
Epicel® is a permanent skin replacement Humanitarian Use Device (“HUD”) indicated for the treatment of adult and pediatric patients with…View ↗
Our current marketed products include two FDA-approved autologous cell therapies and one FDA-approved specialty biologic product. MACI is a…View ↗
Epicel is a permanent skin replacement indicated for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns…View ↗
Our target audiences are orthopedic surgeons who self-identify and/or have formal specialty training in sports medicine, and a…View ↗
Following the approval and commercial launch of NexoBrid, we have expanded the burn care commercial team to include both account management…View ↗
MACI implants, kits and instruments account for most sales and are sold through specialty pharmacies or directly to facilities; Epicel is sold directly to hospitals and NexoBrid through specialty distributors. Most orders are due 30 to 90 days after delivery.
10-K for FY2025, filed Feb 26, 2026The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:View ↗
We contract with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to…View ↗
Following the approval and commercial launch of NexoBrid, we have expanded the burn care commercial team to include both account management…View ↗
For MACI, MACI biopsy kits, MACI Arthro instruments, Epicel and NexoBrid, there are typically no forms of variable consideration related to…View ↗
$276.3M
10-K for FY2025, filed Feb 26, 2026
$276.3M ↗
MACI reaches hospitals through specialty pharmacies or direct sales; Epicel is sold directly to hospitals and burn centers, while specialty distributors resell NexoBrid to those institutions.
10-K for FY2025, filed Feb 26, 2026
Yes. It kept 6 cents of every revenue dollar as net income in FY2025 and turned 9 cents into free cash flow.
8-K, filed Jul 30, 2026
Total revenue of $330 to $340 million, compared to previous guidance of $326 to $336 million MACI revenue of $284 to $290 million, compared…View ↗
Growing. Revenue grew 77% in 4 years, from $156.2M in FY2021 to $276.3M in FY2025, about 15% a year.
NexoBrid moves into commercial sales
The earlier report expected U.S. commercial sales to begin; the latest describes NexoBrid as a marketed product covered by North American license and supply agreements.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026
Arthroscopic MACI moves from development to sale
The earlier report described arthroscopic delivery as under development and awaiting label expansion; the latest reports approved instructions and commercially available instruments.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026As discussed more fully above, MACI is currently implanted into the patient’s cartilage defect through an open surgical procedure. We are…View ↗
Competes with Arthrex, Stryker, ConMed, Zimmer Biomet Holdings, Anika Therapeutics, CartiHeal, Smith & Nephew, Aesculap Biologics, Octane Medical Group, and Avita Medical
10-K for FY2025, filed Feb 26, 2026The main competing treatments for MACI in the U.S. are microfracture and osteochondral allograft. Microfracture, a minimally invasive…View ↗
Loading...